Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients

R Abu-Eid, FJ Ward - Immunology letters, 2021 - Elsevier
Some COVID-19 patients suffer complications from anti-viral immune responses which can
lead to both a dangerous cytokine storm and development of blood-borne factors that render …

PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy

S Fattahi, Z Khalifehzadeh-Esfahani… - Immunologic …, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is a viral infection caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). A single-stranded RNA virus from a β …

The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19

MS Basile, E Cavalli, J McCubrey… - Drug discovery today, 2022 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global
health. The disregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian …

An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy?

G Terrazzano, V Rubino, AT Palatucci… - Frontiers in …, 2020 - frontiersin.org
In December 2019, a novel coronavirus infection appeared in China (Wuhan City and Hubei
Province), causing the first cases of abnormal severe pneumonia. Since then, the SARS …

[HTML][HTML] PI3K/Akt/Nrf2 mediated cellular signaling and virus-host interactions: latest updates on the potential therapeutic management of SARS-CoV-2 infection

VS Lekshmi, K Asha, M Sanicas, A Asi… - Frontiers in Molecular …, 2023 - frontiersin.org
The emergence and re-emergence of viral diseases, which cause significant global mortality
and morbidity, are the major concerns of this decade. Of these, current research is focused …

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection

F Solimani, K Meier, K Ghoreschi - European journal of …, 2021 - Wiley Online Library
Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects
of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial …

PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19

MR Khezri - Human Cell, 2021 - Springer
To the editor Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), poses a major challenge to the world's healthcare …

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

M Catanzaro, F Fagiani, M Racchi, E Corsini… - Signal transduction and …, 2020 - nature.com
To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19
and the current standard care relies on supportive treatments. Therefore, based on the fast …

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

A Mazzoni, L Salvati, L Maggi… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Coronavirus disease 19 (COVID-19) is an emerging infectious disease
caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen …

The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …